|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
6 Davis Drive, Suite 500/PO Box 12878, Durham, NC 27709, US
|
|
Altis has developed a patent-pending stem cell technology recreating the human intestinal epithelium for compound screening and microbiome research. The product is called RepliGut. It will allow drugs to be tested on an in vitro platform that more closely mimics native human biology. Our goal is to enable pharmaceutical companies to identify effective compounds earlier, before clinical trials; to reduce animal testing; and to make the drug development process faster, cheaper, and safer.
Currently, 88% of drugs fail during clinical trials. Part of the reason is that during preclinical studies, drugs are tested using tumor cells and animals. These cannot accurately indicate the way that pharmaceuticals will behave in the human body. The current market lacks a viable method for testing drugs, prior to human testing, and RepliGut will more accurately reflect drug behavior in humans.
|
Altis Biosystems Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Altis Biosystems email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Altis Biosystems customer service number in your country click here to find.
Ben Scruggs is the CEO of Altis Biosystems. To contact Ben Scruggs email at [email protected] or [email protected]. Or you may call +1.3147533292
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.